Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Nanomotor chassis constructed from biological precursors and powered by biocatalytic transformations can offer important applications in the future, specifically in emergent biomedical techniques. Herein, cross β amyloid peptide-based nanomotors (amylobots) were prepared from short amyloid peptides. Owing to their remarkable binding capabilities, these soft constructs are able to host dedicated enzymes to catalyze orthogonal substrates for motility and navigation. Urease helps in powering the self-diffusiophoretic motion, while cytochrome C helps in providing navigation control. Supported by the simulation model, the design principle demonstrates the utilization of two distinct transport behaviours for two different types of enzymes, firstly enhanced diffusivity of urease with increasing fuel (urea) concentration and secondly, chemotactic motility of cytochrome C towards its substrate (pyrogallol). Dual catalytic engines allow the amylobots to be utilized for enhanced catalysis in organic solvent and can thus complement the technological applications of enzymes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516904 | PMC |
| http://dx.doi.org/10.1038/s41467-023-41301-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interactive effects of arterial stiffness and Alzheimer's disease risk on cognitive decline in older adults without dementia.
Alzheimers Dement
September 2025
Research Service, VA San Diego Healthcare System, San Diego, California, USA.
Introduction: Among individuals who are amyloid biomarker-positive or apolipoprotein E (APOE) ε4 carriers, arterial stiffness reflected by higher pulse wave velocity (PWV) has been associated with lower cognition cross-sectionally. Less is known about longitudinal associations.
Methods: The sample included 152 older adults without dementia.
Apolipoprotein E4 allele, antibodies against periodontal microorganisms, and cognition in older adults.
J Alzheimers Dis Rep
September 2025
Communication Sciences and Disorders, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Background: The presence of the apolipoprotein E4 () allele and periodontal disease are independently correlated with higher levels of amyloid-β and inflammation in the brain, worse cognition, and Alzheimer's disease.
Objective: To assess whether the presence of the allele modifies the relationship between IgG antibodies against periodontal microorganisms and cognitive function in older adults participating in the NHANES III study.
Methods: This cross-sectional analysis was conducted among participants of the third National Health and Nutrition Examination Survey (NHANES III) (1988 to 1994), aged 60 years and older, with measurements of IgG antibodies against 19 periodontal microorganisms and alleles (N = 1644).
Neuroavailable peptides from hempseed protein hydrolysates reduce hippocampal inflammation and glial activation in a scopolamine-induced Alzheimer's disease.
Biomed Pharmacother
September 2025
Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, University of Seville, Spain; Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, 41013, Spain. Electronic address:
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment, synaptic dysfunction, and neuronal loss. Neuroinflammation, driven by the activation of microglia and astrocytes, is a key contributor to AD pathology, amplifying oxidative stress and amyloid-β toxicity. Modulation of neuroinflammatory pathways thus represents a promising therapeutic strategy.
View Article and Find Full Text PDFTherapeutic potential of small peptides in Alzheimer's disease: Advances in memory restoration and targeted delivery systems.
Neuropeptides
September 2025
Department of Physiology and Cell Biology, The National Institute for Biotechnology in the Negev, and the School of Brain Sciences and Cognition, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Despite extensive research into Alzheimer's disease (AD), few therapeutic strategies have successfully addressed its core pathology at the synaptic level. Small peptides represent a promising class of therapeutic agents capable of modulating key molecular pathways involved in amyloid toxicity, tau hyperphosphorylation, and synaptic degeneration. Their unique ability to cross biological barriers, interact with intracellular targets, and be modified for enhanced stability positions them as viable candidates for next-generation treatments targeting cognitive decline in AD.
View Article and Find Full Text PDFPrediction of cognitive decline and Alzheimer's disease conversion by a plasma biomarker panel in non-demented individuals.
Geroscience
September 2025
Department of Biological Sciences, College of Natural Sciences, Kangwon National University, Kangwon, 24341, Republic of Korea.
Alzheimer's disease (AD) represents a growing global health burden, underscoring the urgent need for reliable diagnostic and prognostic biomarkers. Although several disease-modifying treatments have recently become available, their effects remain limited, as they primarily delay rather than halt disease progression. Thus, the early and accurate identification of individuals at elevated risk for conversion to AD dementia is crucial to maximize the effectiveness of these therapies and to facilitate timely intervention strategies.
View Article and Find Full Text PDF